Australian & New Zealand Childrens Haematology/Oncology Group
Study Title
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
Protocol ID
AALL1732
Disease (Sub Disease)
Leukaemia (ALL)
Diagnosis Stage
New Diagnosis
Location
NSW, QLD, VIC, WA, SA, NZ
Sponsor
Children's Oncology Group
Collaborators
National Cancer Institute (NCI)
Links
Trial Status
Open
Sites
John Hunter Children's Hospital
Monash Children's Hospital
Perth Children's Hospital
Queensland Children's Hospital
Women's & Children's Hospital
Christchurch Hospital
Starship Hospital
Monash Children's Hospital
Perth Children's Hospital
Queensland Children's Hospital
Women's & Children's Hospital
Christchurch Hospital
Starship Hospital
Study Type
Treatment
Phase
Phase 3
Age Eligibility
1 Year to 24 Years
International registry ID's
NCT03959085
| Study Title | A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL Mixed Phenotype Acute Leukemia and Disseminated B-LLy |
|---|---|
| Protocol ID | AALL1732 |
| Disease (Sub Disease) | Leukaemia (ALL) |
| Diagnosis Stage | New Diagnosis |
| Location | NSW / QLD / VIC / WA / SA / NZ |
| Sponsor | Children's Oncology Group |
| Collaborators | National Cancer Institute (NCI) |
| Links | https://clinicaltrials.gov/ct2/show/NCT03959085 |
| Trial Status | Open |
| Trial Open Date | 28/10/2019 |
| Sites | John Hunter Children's Hospital / Monash Children's Hospital / Perth Children's Hospital / Queensland Children's Hospital / Women's & Children's Hospital / Christchurch Hospital / Starship Hospital |
| Study Type | Treatment |
| Phase | Phase 3 |
| Age Eligibility | 1 Year to 24 Years |
| International registry ID's | NCT03959085 |